THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA , AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, BELARUS, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE. Alvotech (NASDAQ: ...

Alvotech (NASDAQ: ALVO, ALVO-SDB), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has completed its transaction with Xbrane Biopharma AB (“Xbrane”), with the acqusition of the R&D organization of Xbrane in Sweden and biosimilar candidate to Cimzia® (certolizumab pegol). All regulatory conditions have been fulfilled. The transaction, which was announced on March 20, 2025, and approved by Xbrane’s Extraordinary General Meeting on April ...

文章核心观点 全球生物科技公司Alvotech宣布参加2025年杰富瑞全球医疗保健会议，届时管理层将举办一对一会议，首席战略官将进行业务更新展示，公司专注生物类似药研发制造，有产品上市且有研发管线，还建立了战略商业伙伴网络 [1][3] 会议相关信息 - 公司将参加2025年6月3 - 5日在纽约举行的杰富瑞全球医疗保健会议 [1] - 管理层将在会议期间举办一对一会议 [1] - 首席战略官Balaji Prasad博士将于2025年6月5日上午10:30 - 11:00（美国东部时间）进行业务更新展示 [1] - 展示将进行现场视频网络直播，公众可通过https://investors.alvotech.com/events/event-details/jefferies-global-healthcare-conference-nyc-2025观看，活动结束后录像将可供回放90天 [2] 公司概况 - 公司由Robert Wessman创立，专注为全球患者研发和制造生物类似药 [3] - 公司旨在通过集成方法和内部能力提供高质量、低成本产品和服务，成为生物类似药领域全球领导者 [3] - 公司已推出两款生物类似药，研发管线包括针对自身免疫性疾病、眼部疾病、骨质疏松症、呼吸系统疾病和癌症的候选药物 [3] - 公司与多家企业建立战略商业伙伴关系，覆盖美国、欧洲、日本、中国等市场 [3] 联系方式 - 投资者可访问公司投资者门户、网站或在领英、脸书、Instagram和YouTube上关注公司 [4] - 公司投资者关系和全球传播负责人为Benedikt Stefansson，邮箱为alvotech.ir@alvotech.com [5]

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programsThe agreement includes proposed biosimilars to Ilaris® (canakinumab), Kesimpta® (ofatumumab) and an additional early-stage undisclosed biosimilar candidate REYKJAVIK, ICELAND and LONDON, UK (May 28, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Adva ...

文章核心观点 公司公布2025年年度股东大会的召开时间、地点及相关信息获取途径 [1] 分组1 - 股东大会信息 - 2025年6月25日星期三上午9点（欧洲中部夏令时）召开年度股东大会 [1] - 会议地点为卢森堡大公国卢森堡市约翰·F·肯尼迪大道41A号Arendt & Medernach办公场所 [1] - 最终议程见附件文件 [1] - 会议材料和年度股东大会的更多信息可在公司网站查看 [1] 分组2 - 联系方式 - 公司投资者关系联系人是副总裁Benedikt Stefansson [2] - 联系邮箱为alvotech.ir@alvotech.com [2] 分组3 - 附件信息 - 附件为2025年年度股东大会召集通知 [2]

REYKJAVIK, ICELAND AND STOCKHOLM, SWEDEN (May 19, 2025) — Alvotech (NASDAQ: ALVO, the “Company”) has entered into agreement with DNB Carnegie Investment Bank AB (publ) (“DNB Carnegie”) regarding liquidity provider services to ensure liquidity in the Company’s Swedish Depository Receipts (“SDRs”), equity share equivalents, trading on Nasdaq Stockholm. The arrangement is in accordance with the framework of Nasdaq Stockholm’s rules on liquidity providers. In the role of liquidity provider, DNB Carnegie underta ...

Not to be released, published, distributed or circulated in any jurisdiction in which it would be unlawful to do so. This press release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. REYKJAVIK, ICELAND AND STOCKHOLM, SWEDEN (May 19, 2025) — On May 16, 2025 Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced the ...

Not to be released, published, distributed or circulated in any jurisdiction in which it would be unlawful to do so. This press release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. REYKJAVIK, ICELAND AND STOCKHOLM, SWEDEN (May 16, 2025) — Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announces the outcome of ...

纪要涉及的公司 Alvotech (ALVO) 纪要提到的核心观点和论据 1. **公司战略与定位** - 公司自成立起专注于生物仿制药，采用合作模式，拥有超90个国家市场，执行效果良好，目前拥有近30个项目的最大生物仿制药管线 [4][5][7] - 公司具备开发和制造能力，可从细胞系开发到获批全程参与，今年将5个项目投入早期开发，未来每年4 - 6个，且制造与开发协同，执行更高效 [7][8][9] - 短期内不考虑垂直整合，但未来会根据需求和环境变化考虑 [11] 2. **业务成功指标与策略** - 关键决定因素包括总可寻址市场、竞争格局、监管和技术壁垒等，选择高价值项目，注重快速推向市场和选择优质商业伙伴 [13][15] - 生物仿制药不会像仿制药那样价格暴跌，公司通过大量产品发布和非美国市场收入应对价格压力，预计到2028年EBITDA大幅增长 [15][17][19] - 目前倾向于追求至少10亿美元收入项目，随着开发成本降低，可能会关注5 - 10亿美元项目 [21] 3. **财务指标预期** - 以2028年为稳态业务参考，预计收入约15亿美元，产品收入11 - 12亿美元，EBITDA利润率40% - 45%，产品利润率60% - 65% [24][25] 4. **产品市场表现与趋势** - 生物仿制药Stellara在欧洲表现超预期，美国市场仍在形成，预计到年底获得低两位数市场份额 [29][30] - 欧洲市场因单一或有限支付机制，生物仿制药采用曲线更快，美国市场近年来采用速度加快，未来可能更像欧洲 [35][36][37] - Stellara在美国的采用曲线前两年可能类似Humira，预计到2026年底市场转化率达50%，公司有望获低两位数市场份额，私人标签交易仍在市场形成初期 [40] - 美国生物仿制药Stellara定价折扣符合预期，公司有价格底线，不会参与恶性竞争，且已将此因素纳入指导 [45] - 欧洲和非美国市场定价更有利可图、稳定且可持续，公司合作模式按收入分成，不受合作伙伴SG&A成本影响 [47][48][49] - 生物仿制药进入市场后，欧洲市场整体销量大幅增长，美国Humira市场仍有潜力，公司有望获得更多销量优势 [52][53][54] 5. **产能与投资** - 公司现有产能可满足到2032年需求，今年资本支出6000 - 7000万美元，不会大幅增加，随着产品商业化，将获得显著运营杠杆优势 [55][56][59] 6. **产品应对策略** - 针对FDA检查问题，公司有应急计划，与合作伙伴签订MSAs作为业务应急方案 [61][62] - 生物仿制药EYLEA市场，多数竞争对手面临禁令或诉讼，公司有望获批后很快推出，预计明年进入市场 [64][66] - EYLEA高低剂量市场动态仍在演变，公司高剂量版本开发领先，眼科医生对生物仿制药持开放态度 [68][69][71] 7. **合作伙伴关系** - 公司经过广泛筛选选择合作伙伴，如Teva、Doctor Reddy's、Advanced Pharma和Stata等，现有合作伙伴商业实力和声誉良好，预计不会有重大变化 [73][74][75] 其他重要但是可能被忽略的内容 - 公司在细胞系开发方面，过去几个月开发了15种不同细胞系 [8] - 公司开发团队约500人，擅长开发有技术难度的产品 [22] - 公司生物仿制药Stellara使欧洲市场去年增长10% [53]

REYKJAVIK, Iceland, May 09, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the BofA Securities Healthcare Conference 2025, which will be held in Las Vegas, Nevada, May 13-15, 2025. Members of the management team will host one-on-one meetings at the conference. Alvotech will also be participating in a fireside chat on Wednesday, May 14, 2025, at 11:4 ...